Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
Cybin Inc. , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Kernel, a...
Source: marketscreener.com